Is Elevance Health, Inc. (NYSE:ELV) the Best Health Insurance Stock to Buy Now?
"Interest rate cuts + Trump's return" two major expectations continue to ferment! Will this benefiting sector see the dawn?
Market participants believe that in recent three years, the biotechnology sector has been underperforming the broader market. Once the expectation of interest rate cuts is raised by the Fed, biotechnology companies, represented by innovative drugs, will have the ability to make up ground.
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
After the first televised debate for the US presidential election, the first wave of market reactions has arrived!
According to Goldman Sachs, the overall market activity on Friday experienced an explosive growth. Although US inflation cooled down in May, the long-term US Treasury yields reversed the early decline and soared at the close. Barclays recommends buying inflation-protected assets in preparation for Trump's victory.
Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2024 Results on July 17, 2024
Elevance Health (NYSE:ELV) will release second quarter 2024 financial results on July 17, 2024, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call
Investing in Elevance Health (NYSE:ELV) Five Years Ago Would Have Delivered You a 103% Gain
Elevance Health Insiders Sell US$9.2m Of Stock, Possibly Signalling Caution
The fact that multiple Elevance Health, Inc. (NYSE:ELV) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. Knowing whether insid
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Morgan Stanley Says Elevance Health's Growth Attributed To Consistent Performance But Undervalued
Morgan Stanley has initiated coverage on Elevance Health Inc (NYSE:ELV), an American health insurance provider formerly Anthem Inc, citing compelling risk-reward.
16 Analysts Have This To Say About Elevance Health
Elevance Health (NYSE:ELV) has been analyzed by 16 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The following table encapsulates their recent ra
Elevance Health Initiated at Overweight by Morgan Stanley
Elevance Health Initiated at Overweight by Morgan Stanley
Morgan Stanley Initiates Coverage On Elevance Health With Overweight Rating, Announces Price Target of $643
Morgan Stanley analyst Erin Wright initiates coverage on Elevance Health (NYSE:ELV) with a Overweight rating and announces Price Target of $643.
Elevance Health Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/24/2024 20.32% Morgan Stanley → $643 Initiates Coverage On → Overweight 06/12/2024 12.27% Cantor Fitzge
Morgan Stanley Initiates Elevance Health(ELV.US) With Buy Rating, Announces Target Price $643
Morgan Stanley analyst Erin Wright initiates coverage on $Elevance Health(ELV.US)$ with a buy rating, and sets the target price at $643.According to TipRanks data, the analyst has a success rate of 66
Elevance Health (ELV) Rallies 11.8% YTD: More Room to Run?
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Elevance Health, Inc. (ELV): A Feminist Stock That Benefits From Health Care Growth
Elevance Health Insiders Sold US$9.2m Of Shares Suggesting Hesitancy
CMS to Recalculate Ratings for 2024 Medicare Advantage Plans
Why Elevance Health, Inc. (NYSE:ELV) Could Be Worth Watching